A. Herrick, The pathogenesis, diagnosis and treatment of Raynaud phenomenon, Nature Reviews Rheumatology, vol.23, issue.8, pp.469-79, 2012.
DOI : 10.1038/nrrheum.2012.96

A. Herrick, Pathogenesis of Raynaud's phenomenon, Rheumatology, vol.44, issue.5, pp.587-96, 2005.
DOI : 10.1093/rheumatology/keh552

M. Weinrich, H. Maricq, J. Keil, A. Mcgregor, and F. Diat, Prevalence of raynaud phenomenon in the adult population of South Carolina, Journal of Clinical Epidemiology, vol.43, issue.12, pp.1343-1352, 1990.
DOI : 10.1016/0895-4356(90)90101-T

D. Angelis, R. Salaffi, F. Grassi, and W. , Raynaud's phenomenon: prevalence in an Italian population sample, Clinical Rheumatology, vol.22, issue.suppl, pp.506-516, 2006.
DOI : 10.1007/s10067-005-0077-1

A. Silman, S. Holligan, P. Brennan, and P. Maddison, Prevalence of symptoms of Raynaud's phenomenon in general practice., BMJ, vol.301, issue.6752, p.590, 1990.
DOI : 10.1136/bmj.301.6752.590

L. Suter, J. Murabito, D. Felson, and L. Fraenkel, The incidence and natural history of Raynaud's phenomenon in the community, Arthritis & Rheumatism, vol.21, issue.4, pp.1259-63, 2005.
DOI : 10.1002/art.20988

F. Wigley, A. Herrick, and N. Flavahan, Raynaud's Phenomenon [Internet], Disponible sur, pp.978-979, 2015.

J. Winchester and A. Kennedy, Iatrogenic Raynaud's phenomenon., BMJ, vol.3, issue.5766, p.113, 1971.
DOI : 10.1136/bmj.3.5766.113-b

N. Flavahan, A vascular mechanistic approach to understanding Raynaud phenomenon, Nature Reviews Rheumatology, vol.273, issue.3, pp.146-58, 2015.
DOI : 10.1046/j.1439-0264.2000.00280.x

M. Roustit and J. Cracowski, Assessment of endothelial and neurovascular function in human skin microcirculation, Trends in Pharmacological Sciences, vol.34, issue.7, pp.373-84, 2013.
DOI : 10.1016/j.tips.2013.05.007

URL : https://hal.archives-ouvertes.fr/inserm-00851114

R. Freedman, M. Moten, P. Migály, and M. Mayes, Cold-induced potentiation of ??2-adrenergic vasoconstriction in primary raynaud's disease, Arthritis & Rheumatism, vol.44, issue.5, pp.685-90, 1993.
DOI : 10.1002/art.1780360517

J. Coffman and H. Rasmussen, Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon. Circulation. 1 sept, pp.466-70, 1985.

M. Heintzen and B. Strauer, Peripheral Vascular Effects of Beta-Blockers, European Heart Journal, vol.15, issue.suppl C, pp.2-7, 1994.
DOI : 10.1093/eurheartj/15.suppl_C.2

C. Franssen, H. Wollersheim, A. De-haan, and T. Thien, The Influence of Different Beta-Blocking Drugs on the Peripheral Circulation in Raynaud's Phenomenon and in Hypertension, The Journal of Clinical Pharmacology, vol.71, issue.suppl V, pp.652-661, 1992.
DOI : 10.1002/j.1552-4604.1992.tb05777.x

J. Steiner, R. Cooper, J. Gear, and J. Ledingham, Vascular symptoms in patients with primary Raynaud's phenomenon are not exacerbated by propranolol or labetalol., British Journal of Clinical Pharmacology, vol.83, issue.4, pp.401-404, 1979.
DOI : 10.1111/j.1365-2125.1979.tb00953.x

E. Feleke, O. Lyngstam, L. Råstam, and L. Rydén, Complaints of Cold Extremities among Patients on Antihypertensive Treatment, Acta Medica Scandinavica, vol.1, issue.Suppl 4, pp.381-386, 1983.
DOI : 10.1111/j.0954-6820.1983.tb03755.x

M. Vandenburg, S. Evans, W. Cooper, F. Bradshaw, and W. Currie, Is the feeling of cold extremities experienced by hypertensive patients due to their disease or their treatment?, European Journal of Clinical Pharmacology, vol.14, issue.Suppl 1, pp.47-56, 1984.
DOI : 10.1007/BF02395205

H. Lithell, T. Pollare, and B. Vessby, Metabolic Effects of Pindolol and Propranolol in a Double-Blind Cross-Over Study in Hypertensive Patients, Blood Pressure, vol.82, issue.2, pp.92-101, 1992.
DOI : 10.1055/s-2007-1014753

P. Tfelt-hansen, P. Saxena, C. Dahlöf, J. Pascual, M. Láinez et al., Ergotamine in the acute treatment of migraine: A review and European consensus, Brain, vol.123, issue.1, pp.9-18, 2000.
DOI : 10.1093/brain/123.1.9

C. Dahlöf, M. Van-den, and A. Brink, Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan - Basic Science in Relation to Migraine Treatment, Headache: The Journal of Head and Face Pain, vol.238, issue.1, pp.707-721, 2012.
DOI : 10.1111/j.1526-4610.2012.02124.x

A. Gilman and T. Rall, Goodman and gilman's the pharmacological basis of thera peutics, Disponible sur, 1985.

D. Mccrory and R. Gray, Oral sumatriptan for acute migraine, Disponible sur, 2012.

T. Hahne and B. Balda, Fingerkuppennekrosen nach Dihydroergotaminmedikation bei limitierter systemischer Sklerodermie, Der Hautarzt, vol.49, issue.9, pp.722-726, 1998.
DOI : 10.1007/s001050050816

L. Robb, Severe vasospasm following ergot administration, West J Med. sept, vol.123, issue.3, pp.231-236, 1975.

O. Keeffe, S. Tsapatsaris, N. Beetham, and W. Jr, Association between Raynaud's phenomenon and migraine in a random population of hospital employees, J Rheumatol. juill, vol.20, issue.7, pp.1187-1195, 1993.

I. Zahavi, A. Chagnac, R. Hering, S. Davidovich, and A. Kuritzky, Prevalence of Raynaud's Phenomenon in Patients With Migraine, Archives of Internal Medicine, vol.144, issue.4, pp.742-746, 1984.
DOI : 10.1001/archinte.1984.00350160096017

R. Duvoisin, DIGITAL VASOSPASM WITH BROMOCRIPTINE, The Lancet, vol.308, issue.7978, p.204, 1976.
DOI : 10.1016/S0140-6736(76)92381-3

J. Quagliarello and R. Barakat, Raynaud???s phenomenon in infertile women treated with bromocriptine, Fertility and Sterility, vol.48, issue.5, pp.877-886, 1987.
DOI : 10.1016/S0015-0282(16)59548-X

T. Zenone, I. Durieu, F. Nagnoug, P. Castell, and R. Levrat, Raynaud phenomenon with organic microangiopathy and prolonged treatment with bromocriptine]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, pp.948-50, 1996.

D. Cruaud, G. Noël, and M. Daumont, [Raynaud's syndrome induced by bromoergocryptine]. Nouv Presse Médicale. 17 sept, p.2693, 1977.

D. Leeuw-van-weenen, J. Parlevliet, E. Maechler, P. Havekes, L. Romijn et al., The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the ??2-adrenergic receptors in beta cells, Biochemical Pharmacology, vol.79, issue.12, pp.1827-1863, 2010.
DOI : 10.1016/j.bcp.2010.01.029

M. Arbouw, K. Movig, H. Guchelaar, C. Neef, and T. Egberts, Dopamine agonists and ischemic complications in Parkinson???s disease: a nested case???control study, European Journal of Clinical Pharmacology, vol.18, issue.Pt 1, pp.83-91, 2012.
DOI : 10.1007/s00228-011-1084-6

B. Coleiro, S. Marshall, C. Denton, K. Howell, A. Blann et al., Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine, Rheumatology, vol.40, issue.9, pp.1038-1081, 2001.
DOI : 10.1093/rheumatology/40.9.1038

J. Rey, E. Cretel, R. Jean, M. Pastor, and J. Durand, Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia, Rheumatology, vol.42, issue.4, pp.601-603, 2003.
DOI : 10.1093/rheumatology/keg137

A. Buecking, E. Rougemont, F. Zullino, and D. , Treatment of Raynaud's phenomenon with escitalopram, The International Journal of Neuropsychopharmacology, vol.8, issue.2, pp.307-315, 2005.
DOI : 10.1017/S1461145704004882

D. Broucker, T. Lhote, and F. , Severe Raynaud's phenomenon associated with interferonbeta 1a and fluoxetine], Ann Médecine Interne. sept, vol.151, issue.5, pp.424-429, 2000.

A. Rudnick, I. Modai, and A. Zelikovski, Fluoxetine-induced Raynaud's phenomenon, Biological Psychiatry, vol.41, issue.12, pp.1218-1239, 1997.
DOI : 10.1016/S0006-3223(97)00188-1

C. Bell, N. Coupland, and P. Creamer, Digital Infarction in a Patient with Raynaud's Phenomenon Associated with Treatment with a Specific Serotonin Reuptake Inhibitor: A Case Report, Angiology, vol.47, issue.9, pp.901-904, 1996.
DOI : 10.1177/000331979604700909

A. Peiró, C. Margarit, and M. Torra, Citalopram-induced Raynaud???s phenomenon, Rheumatology International, vol.146, issue.6, pp.599-601, 2006.
DOI : 10.1007/s00296-006-0254-9

B. Bourgade, A. Jonville-béra, L. Garé, C. Ferquel, D. Autret-leca et al., Raynaud's Syndrome in a Patient Treated with Milnacipran, Annals of Pharmacotherapy, vol.345, issue.9, pp.1009-1019, 1999.
DOI : 10.1345/aph.18402

D. Rudikoff and I. Jaffe, Erythromelalgia: Response to serotonin reuptake inhibitors, Journal of the American Academy of Dermatology, vol.37, issue.2, pp.281-284, 1997.
DOI : 10.1016/S0190-9622(97)80144-2

R. Bertoli, F. Girardin, S. Russmann, and B. Lauterburg, Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod, European Journal of Clinical Pharmacology, vol.92, issue.10, pp.717-717, 2003.
DOI : 10.1016/S0006-3223(97)00188-1

C. Garcia-porrua, C. Margarinos, and M. Gonzalez-gay, Raynaud's phenomenon and serotonin reuptake inhibitors, J Rheumatol. oct, vol.31, issue.10, pp.2090-2090, 2004.

R. Syed and T. Moore, Methylphenidate and Dextroamphetamine-Induced Peripheral Vasculopathy, JCR: Journal of Clinical Rheumatology, vol.14, issue.1, pp.30-33, 2008.
DOI : 10.1097/RHU.0b013e3181639aaa

W. Goldman, R. Seltzer, and P. Reuman, Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: A retrospective case???control study of rheumatology patients, Arthritis & Rheumatism, vol.90, issue.2, pp.563-569, 2008.
DOI : 10.1002/art.23301

C. Gökçen, M. Kutuk, and S. Co?kun, Dose-Dependent Raynaud's Phenomenon Developing from Use of Atomoxetine in a Girl, Journal of Child and Adolescent Psychopharmacology, vol.23, issue.6, pp.428-458, 2013.
DOI : 10.1089/cap.2012.0131

H. Jefferson and D. Jayne, Peripheral vasculopathy and nephropathy in association with phentermine, Nephrology Dialysis Transplantation, vol.14, issue.7, pp.1761-1764, 1999.
DOI : 10.1093/ndt/14.7.1761

V. Ravindran and S. Rajendran, Digital gangrene in a patient with primary Raynaud???s phenomenon, The Journal of the Royal College of Physicians of Edinburgh, vol.42, issue.1, pp.24-30, 2012.
DOI : 10.4997/JRCPE.2012.106

C. Francès, Y. Allanore, J. Cabane, P. Carpentier, C. Dumontier et al., Prise en charge des ulc??res digitaux de la scl??rodermie syst??mique, La Presse M??dicale, vol.37, issue.2, pp.271-85, 2008.
DOI : 10.1016/j.lpm.2007.07.006

A. Balbir-gurman, Y. Braun-moscovici, and A. Nahir, Cocaine-Induced Raynaud???s Phenomenon and Ischaemic Finger Necrosis, Clinical Rheumatology, vol.20, issue.5, pp.376-384, 2001.
DOI : 10.1007/s100670170031

E. Eichhorn, S. Demian, L. Alvarez, J. Willard, S. Molina et al., Cocaine-induced alterations in prostaglandin production in rabbit aorta, Journal of the American College of Cardiology, vol.19, issue.3, pp.696-703, 1992.
DOI : 10.1016/S0735-1097(10)80295-5

S. Rezkalla, J. Mazza, R. Kloner, V. Tillema, and S. Chang, Effects of cocaine on human platelets in healthy subjects, The American Journal of Cardiology, vol.72, issue.2, pp.243-249, 1993.
DOI : 10.1016/0002-9149(93)90173-A

B. Noel, Cocaine and Arsenic-Induced Raynaud???s Phenomenon, Clinical Rheumatology, vol.2, issue.4, pp.343-347, 2002.
DOI : 10.1007/s100670200091

V. Marder and I. Mellinghoff, Cocaine and Buerger Disease, Archives of Internal Medicine, vol.160, issue.13, pp.2057-60, 2000.
DOI : 10.1001/archinte.160.13.2057

P. Kumar and H. Smith, Cocaine-Related Vasculitis Causing Upper-Limb Peripheral Vascular Disease, Annals of Internal Medicine, vol.133, issue.11, pp.923-927, 2000.
DOI : 10.7326/0003-4819-133-11-200012050-00026

A. Gröger, A. Aslani, T. Wolter, E. Noah, and N. Pallua, A rare case of Cannabis arteritis, Vasa, vol.32, issue.2, pp.95-102, 2003.
DOI : 10.1024/0301-1526.32.2.95

F. Schneider, N. Abdoucheli-baudot, M. Tassart, F. Boudghène, and P. Gouny, Cannabis and tobacco: cofactors favoring juvenile obliterative arteriopathy], J Mal Vasc. déc, vol.25, issue.5, pp.388-397, 2000.

T. Stefenelli, R. Kuzmits, W. Ulrich, and D. Glogar, Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer, European Heart Journal, vol.9, issue.5, pp.552-558, 1988.
DOI : 10.1093/oxfordjournals.eurheartj.a062542

C. Teutsch, A. Lipton, and H. Harvey, Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma, Cancer Treat Rep. août, vol.61, issue.5, pp.925-931, 1977.

C. Berger, C. Bokemeyer, M. Schneider, M. Kuczyk, and H. Schmoll, Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer, European Journal of Cancer, vol.31, issue.13-14, pp.13-142229, 1990.
DOI : 10.1016/0959-8049(95)00460-2

M. Heier, T. Nilsen, V. Graver, N. Aass, and S. Fosså, Raynaud's phenomenon after combination chemotherapy of testicular cancer, measured by laser Doppler flowmetry. A pilot study, British Journal of Cancer, vol.63, issue.4, p.550, 1991.
DOI : 10.1038/bjc.1991.129

J. Glendenning, Y. Barbachano, A. Norman, D. Dearnaley, A. Horwich et al., Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer, Cancer, vol.69, 2010.
DOI : 10.1002/cncr.24981

M. Brydøy, J. Oldenburg, O. Klepp, R. Bremnes, E. Wist et al., Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors, JNCI Journal of the National Cancer Institute, vol.101, issue.24, pp.1682-95, 2009.
DOI : 10.1093/jnci/djp413

M. Reiser, C. Bruns, P. Hartmann, B. Salzberger, V. Diehl et al., Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma, European Journal of Clinical Microbiology & Infectious Diseases, vol.336, issue.1, pp.58-60, 1998.
DOI : 10.1007/BF01584368

M. Hladunewich, C. Sawka, A. Fam, and E. Franssen, Raynaud's phenomenon and digital gangrene as a consequence of treatment for Kaposi's sarcoma, J Rheumatol. déc, vol.24, issue.12, pp.2371-2376, 1997.

M. Pechère, G. Zulian, J. Vogel, M. Jeanprêtre, B. Hirschel et al., Fingertip necrosis during chemotherapy with bleomycin, vincristine and methotrexate for HIV-related Kaposi's sarcoma, British Journal of Dermatology, vol.64, issue.2, pp.378-387, 1996.
DOI : 10.1016/0002-9343(92)90589-4

R. Fertakos and D. Mintzer, Digital gangrene following chemotherapy for aids-related Kaposi's sarcoma, The American Journal of Medicine, vol.93, issue.5, pp.581-583, 1992.
DOI : 10.1016/0002-9343(92)90589-4

V. Gunten, C. Roth, E. , V. Roenn, and J. , Raynaud phenomenon in three patients with acquired immune deficiency syndrome-related kaposi sarcoma treated with bleomycin, Cancer, vol.15, issue.6, 1993.
DOI : 10.1002/1097-0142(19930915)72:6<2004::AID-CNCR2820720635>3.0.CO;2-5

S. Mcgrath, A. Webb, and K. Walker-bone, Bleomycin-Induced Raynaud's Phenomenon After Single-Dose Exposure: Risk Factors and Treatment With Intravenous Iloprost Infusion, Journal of Clinical Oncology, vol.31, issue.4, pp.51-53, 2013.
DOI : 10.1200/JCO.2012.43.2872

E. Epstein, Intralesional bleomycin and Raynaud's phenomenon, Journal of the American Academy of Dermatology, vol.24, issue.5, pp.785-791, 1991.
DOI : 10.1016/S0190-9622(08)80370-2

E. Epstein, Persisting Raynaud's phenomenon following intralesional bleomycin treatment of finger warts, Journal of the American Academy of Dermatology, vol.13, issue.3, pp.468-71, 1985.
DOI : 10.1016/S0190-9622(85)80353-4

L. Gregg, Intralesional bleomycin and Raynaud's phenomenon, Journal of the American Academy of Dermatology, vol.26, issue.2, pp.279-80, 1992.
DOI : 10.1016/S0190-9622(08)80323-4

O. Vanhooteghem, B. Richert, and M. De-la-brassinne, Raynaud Phenomenon After Treatment of Verruca Vulgaris of the Sole with Intralesional Injection of Bleomycin, Pediatric Dermatology, vol.69, issue.1 pt 1, pp.249-51, 2001.
DOI : 10.1046/j.1525-1470.2001.018003249.x

D. Pablo, P. Aguillar, A. Gallego, and M. , Raynaud's phenomenon and intralesional bleomycin, Acta Derm Venereol. nov, vol.72, issue.6, p.465, 1992.

S. Fosså, G. Lehne, K. Heimdal, and L. Theodorsen, Clinical and Biochemical Long???Term Toxicity after Postoperative Cisplatin???Based Chemotherapy in Patients with Low-Stage Testicular Cancer, Oncology, vol.52, issue.4, pp.300-305, 1995.
DOI : 10.1159/000227478

M. Mohokum, P. Hartmann, and P. Schlattmann, The association of Raynaud's syndrome with cisplatin-based chemotherapy ??? A meta-analysis, European Journal of Internal Medicine, vol.23, issue.7, pp.594-602, 2012.
DOI : 10.1016/j.ejim.2012.03.016

C. Kuhar, T. Mesti, and B. Zakotnik, Digital ischemic events related to gemcitabine: Report of two cases and a systematic review, Radiology and Oncology, vol.44, issue.4, pp.257-61, 2010.
DOI : 10.2478/v10019-010-0020-1

C. Zaima, M. Kanai, S. Ishikawa, Y. Kawaguchi, T. Masui et al., A Case of Progressive Digital Ischemia after Early Withdrawal of Gemcitabine and S-1 in a Patient with Systemic Sclerosis, Japanese Journal of Clinical Oncology, vol.41, issue.6, pp.803-809, 2011.
DOI : 10.1093/jjco/hyr045

D. 'alessandro, V. Errico, M. Varriale, A. Greco, A. et al., Case report: Acro-necrosis of the upper limbs caused by gemcitabine therapy], Clin Ter. juin, vol.154, issue.3, pp.207-217, 2003.

S. Gottschling, S. Meyer, R. H. Krenn, T. Graf, and N. , First Report of a Vincristine Dose-Related Raynaud's Phenomenon in an Adolescent With Malignant Brain Tumor, Journal of Pediatric Hematology/Oncology, vol.26, issue.11, pp.768-777, 2004.
DOI : 10.1097/00043426-200411000-00017

D. Papamichael, N. Amft, M. Slevin, D. Cruz, and D. , 5-Fluorouracil-induced Raynaud's phenomenon, Eur J Cancer Oxf Engl nov, vol.34, issue.12, 1983.

K. Karabacak, M. Kadan, E. Kaya, B. Durgun, G. Arslan et al., Oxaliplatin Induced Digital Ischemia and Necrosis. Case Rep Vasc Med, p.248748, 2015.

M. Seishima, T. Izumi, and H. Kanoh, Raynaud's phenomenon possibly induced by a compund drug of tegafur and uracil, Eur J Dermatol EJD. févr, vol.10, issue.1, pp.55-63, 2000.

D. Angelis, R. Silveri, F. Bugatti, L. Filosa, and G. , Raynaud???s Phenomenon after Combined Adjuvant Chemotherapy for Breast Cancer, Chemotherapy, vol.49, issue.5, pp.267-275, 2003.
DOI : 10.1159/000072453

S. Hansen and N. Olsen, Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold., Journal of Clinical Oncology, vol.7, issue.7, pp.940-942, 1989.
DOI : 10.1200/JCO.1989.7.7.940

S. Hansen, N. Olsen, N. Rossing, and M. Rørth, Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinbiastine and bleomycin, Annals of Oncology, vol.1, issue.4, pp.289-92, 1990.
DOI : 10.1093/oxfordjournals.annonc.a057750

M. Meinardi, J. Gietema, W. Graaf, . Van-der, D. Veldhuisen et al., Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer, Journal of Clinical Oncology, vol.18, issue.8, pp.1725-1757, 2000.
DOI : 10.1200/JCO.2000.18.8.1725

F. Batteux, N. Kavian, and A. Servettaz, New insights on chemically induced animal models of systemic sclerosis, Current Opinion in Rheumatology, vol.23, issue.6, pp.511-519, 2011.
DOI : 10.1097/BOR.0b013e32834b1606

H. Freudiger, H. Bounameaux, and J. Garcia, Acroosteolysis and Raynaud's phenomenon after vinyl chloride exposure, VASA Z Für Gefässkrankh, vol.17, issue.3, pp.216-224, 1988.

P. Falappa, N. Magnavita, A. Bergamaschi, and N. Colavita, Angiographic study of digital arteries in workers exposed to vinyl chloride., Occupational and Environmental Medicine, vol.39, issue.2, pp.169-72, 1982.
DOI : 10.1136/oem.39.2.169

H. Maricq, M. Johnson, C. Whetstone, and E. Leroy, Capillary abnormalities in polyvinyl chloride production workers. Examination by in vivo microscopy, JAMA: The Journal of the American Medical Association, vol.236, issue.12, pp.1368-71, 1976.
DOI : 10.1001/jama.236.12.1368

L. Fontana, M. Marion, S. Ughetto, and P. Catilina, Glutathione S-transferase M1 and GST T1 genetic polymorphisms and Raynaud???s phenomenon in French vinyl chloride monomer-exposed workers, Journal of Human Genetics, vol.11, issue.37, pp.879-86, 2006.
DOI : 10.1007/s10038-006-0038-9

A. Laplanche, F. Clavel, J. Contassot, and C. Lanouziere, Exposure to vinyl chloride monomer: report on a cohort study., Occupational and Environmental Medicine, vol.44, issue.10, pp.711-716, 1987.
DOI : 10.1136/oem.44.10.711

H. Al-zahrani, V. Gupta, M. Minden, H. Messner, and J. Lipton, Vascular Events Associated with Alpha Interferon Therapy, Leukemia & Lymphoma, vol.125, issue.3, pp.471-476, 2003.
DOI : 10.1006/mvre.1996.0066

W. Kruit, A. Eggermont, and G. Stoter, Interferon-? induced Raynaud's syndrome

B. Cruz, E. Queiroz, S. Nunes, C. Filho, A. Campos et al., F??nomeno de Raynaud grave associado a terapia com interferon-beta para esclerose m??ltipla: relato de caso, Arquivos de Neuro-Psiquiatria, vol.58, issue.2B, pp.556-565, 2000.
DOI : 10.1590/S0004-282X2000000300025

A. Campo-voegeli, T. Estrach, R. Marti, N. Corominas, M. Tuset et al., Acrocyanosis Induced by Interferon ??<sub>2a</sub>, Dermatology, vol.196, issue.3, pp.361-364, 1998.
DOI : 10.1159/000017917

E. Liozon, L. Delaire, P. Lacroix, F. Labrousse, K. Ly et al., Raynaud syndrome complicated by digital gangrene during treatment with interferon-alpha]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, pp.316-325, 1997.

U. Rot and A. Ledinek, Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis, Clinical Neurology and Neurosurgery, vol.115, pp.79-81, 2013.
DOI : 10.1016/j.clineuro.2013.09.027

?. Husein, H. Elahmed, ?. Callejas, J. Rubio, R. Olmo et al., Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma, Curr Oncol. août, vol.17, issue.4, pp.122-125, 2010.

C. Bachmeyer, D. Farge, E. Gluckman, J. Miclea, and S. Aractingi, Raynaud's phenomenon and digital necrosis induced by interferon-alpha, British Journal of Dermatology, vol.81, issue.3, pp.481-484, 1996.
DOI : 10.1001/archderm.128.4.566

M. Arslan, E. Ozyilkan, B. Kayhan, and H. Telatar, LETTER TO THE EDITOR, Journal of Internal Medicine, vol.115, issue.5, p.503, 1994.
DOI : 10.1111/j.1365-2796.1994.tb01111.x

A. Creutzig, L. Caspary, and M. Freund, The Raynaud Phenomenon and Interferon Therapy, Annals of Internal Medicine, vol.125, issue.5, p.423, 1996.
DOI : 10.7326/0003-4819-125-5-199609010-00025

D. Schapira, A. Nahir, and N. Hadad, Interferon-induced Raynaud's syndrome, Seminars in Arthritis and Rheumatism, vol.32, issue.3, pp.157-62, 2002.
DOI : 10.1053/sarh.2002.34606

M. Mohokum, P. Hartmann, and P. Schlattmann, Association of Raynaud's syndrome with interferons. A meta-analysis, Int Angiol J Int Union Angiol. oct, vol.31, issue.5, pp.408-421, 2012.

A. Zeidman, D. Dicker, and M. Mittelman, Interferon-Induced Vasospasm in Chronic Myeloid Leukaemia, Acta Haematologica, vol.100, issue.2, pp.94-100, 1998.
DOI : 10.1159/000040874

F. Cozzolino, M. Torcia, M. Lucibello, L. Morbidelli, M. Ziche et al., Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth., Journal of Clinical Investigation, vol.91, issue.6, pp.2504-2516, 1993.
DOI : 10.1172/JCI116486

R. Iorio, M. Spagnuolo, A. Sepe, S. Zoccali, M. Alessio et al., Severe Raynaud's phenomenon with chronic hepatis C disease treated with interferon, Pediatr Infect Dis J. févr, vol.22, issue.2, pp.195-202, 2003.

T. Vial and J. Descotes, Clinical Toxicity of the Interferons, Drug Safety, vol.10, issue.2, pp.115-50, 1994.
DOI : 10.2165/00002018-199410020-00003

E. Tóthová, A. Kafková, N. Stecová, M. Fricová, T. Guman et al., Immunemediated complications during interferon alpha therapy in chronic myelogenous leukemia, Neoplasma, vol.49, issue.2, pp.91-95, 2002.

V. Roy and A. Newland, RAYNAUD'S PHENOMENON AND CRYOGLOBULINAEMIA ASSOCIATED WITH THE USE OF RECOMBINANT HUMAN ALPHA-INTERFERON, The Lancet, vol.331, issue.8591, pp.944-949, 1988.
DOI : 10.1016/S0140-6736(88)91759-X

A. Raza, S. Mittal, and G. Sood, Interferon-associated retinopathy during the treatment of chronic hepatitis C: a systematic review, Journal of Viral Hepatitis, vol.144, issue.9, pp.593-602, 2013.
DOI : 10.1111/jvh.12135

P. Willeke, B. Schlüter, H. Schotte, W. Domschke, M. Gaubitz et al., Interferon-?? Is Increased in Patients with Primary Sjogren's Syndrome and Raynaud's Phenomenon, Seminars in Arthritis and Rheumatism, vol.39, issue.3, pp.197-202, 2009.
DOI : 10.1016/j.semarthrit.2008.04.002

A. Davenport, The effect of renal transplantation and treatment with cyclosporin A on the prevalence of Raynaud's phenomenon, Clin Transplant, vol.7, issue.1, pp.4-8, 1993.

T. Arinsoy, U. Derici, A. Yuksel, K. Reis, and S. Sindel, Cyclosporine - a treatment and a rare complication: Raynaud's phenomenon, International Journal of Clinical Practice, vol.29, issue.7, pp.863-867, 2005.
DOI : 10.1111/j.1368-5031.2005.00566a.x

G. Deray, L. Hoang, P. Achour, L. Hornych, A. Landault et al., The Lancet, nov, vol.328, issue.8515, pp.1092-1095, 1986.

A. Sharma, S. Sunil, R. Rustom, J. Bone, A. Hammad et al., Cyclosporin A-related Raynaud's phenomenon in a renal transplant recipient, Transplant International, vol.29, issue.9-10, pp.9-10517, 2002.
DOI : 10.1016/S0140-6736(84)91964-0

E. Osman, J. Barrett, M. Bewick, and V. Parsons, Does cyclosporin affect renal blood vessels? Lancet. 30 juin, p.1470, 1984.

P. Furspan, S. Chatterjee, and R. Freedman, Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease, Arthritis & Rheumatism, vol.131, issue.5, pp.1578-85, 2004.
DOI : 10.1002/art.20214

Z. Tamaki, Y. Asano, M. Hatano, A. Yao, T. Kawashima et al., Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases, Modern Rheumatology, vol.47, issue.5, pp.94-103, 2012.
DOI : 10.1200/JCO.2009.25.0779

C. Hazenberg, G. Ossenkoppele, and W. Smit, Raynaud-like phenomenon in two patients on nilotinib, British Journal of Haematology, vol.158, issue.4, p.431, 2012.
DOI : 10.1111/j.1365-2141.2012.09215.x

A. Quintás-cardama, H. Kantarjian, and J. Cortes, Nilotinib-Associated Vascular Events, Clinical Lymphoma Myeloma and Leukemia, vol.12, issue.5, pp.337-377, 2012.
DOI : 10.1016/j.clml.2012.04.005

P. Ballardini, G. Margutti, and R. Manfredini, Digital necrosis induced by erlotinib treatment in metastatic adenocarcinoma of the lung, Current Oncology, vol.18, issue.3, pp.109-119, 2011.
DOI : 10.3747/co.v18i3.782

J. Schmutz, A. Barbaud, and P. Tréchot, Fluoresc??ine par voie intraveineuse et syndrome de Raynaud, Annales de Dermatologie et de V??n??r??ologie, vol.136, issue.1, p.96, 2009.
DOI : 10.1016/j.annder.2008.10.025

P. Blaise, C. Ribbens, and J. Rakic, Fluorescein-induced Raynaud's phenomenon, Acta Ophthalmologica Scandinavica, vol.93, issue.8, pp.910-911, 2007.
DOI : 10.1111/j.1600-0420.2007.00953.x

J. Ahmad, M. Siddiqui, A. Khan, and S. Afzall, Raynaud's phenomenon induced by sulphasalazine in a case of chronic ulcerative colitis, J Assoc Physicians India. avr, vol.32, issue.4, p.370, 1984.

J. Reid, S. Holt, E. Housley, and D. Sneddon, Raynaud's phenomenon induced by sulphasalazine., Postgraduate Medical Journal, vol.56, issue.652, pp.106-113, 1980.
DOI : 10.1136/pgmj.56.652.106

P. Dodd and G. Biswas, Raynauld's phenomenon and propofol, Anaesthesia, vol.82, issue.3, p.918, 1999.
DOI : 10.1046/j.1365-2044.1999.01096.x

B. Zernikow, G. Fleischhack, C. Hasan, and U. Bode, Cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B: three case reports, Mycoses, vol.3, issue.9-10, pp.9-10359, 1997.
DOI : 10.1111/j.1439-0507.1997.tb00250.x

R. Barreira, B. García, M. López, I. Legazpi, H. Díaz et al., Paradoxical Reaction of Raynaud Phenomenon Following the Repeated Administration of Iloprost in a Patient with Diffuse Cutaneous Systemic Sclerosis, Annals of Pharmacotherapy, vol.46, issue.10, pp.28-28, 2012.
DOI : 10.1345/aph.1R093

S. Johnson, J. Iazzetta, and C. Dewar, Severe Raynaud's phenomenon with yohimbine therapy for erectile dysfunction, J Rheumatol. nov, vol.30, issue.11, pp.2503-2508, 2003.

A. Marshall, C. Roberts, and D. Barritt, Raynaud's phenomenon as side effect of beta-blockers in hypertension., BMJ, vol.1, issue.6024, p.1498, 1976.
DOI : 10.1136/bmj.1.6024.1498

F. Wigley, Raynaud's Phenomenon, New England Journal of Medicine, vol.347, issue.13, pp.1001-1009, 2002.
DOI : 10.1056/NEJMcp013013

W. Martindale and S. Sweetman, Martindale: the complete drug reference [Internet] Pharmaceutical press London, Disponible sur, 1999.

B. Katzung, S. Masters, and A. Trevor, Basic & clinical pharmacology, Disponible sur, 2004.

F. Brand, M. Larson, W. Kannel, and J. Mcguirk, The Occurrence of Raynaud's Phenomenon in a General Population: The Framingham Study, Vascular Medicine, vol.89, issue.1, pp.296-301, 1997.
DOI : 10.1016/0895-4356(90)90101-T

M. Mohokum, P. Hartmann, and P. Schlattmann, The Association of Raynaud Syndrome With ??-Blockers, Angiology, vol.24, issue.5, pp.535-575, 2012.
DOI : 10.1136/bmj.b2700

Y. Lacourcière, J. Lefebvre, P. Provencher, and L. Poirier, Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring., British Journal of Clinical Pharmacology, vol.1, issue.Suppl., pp.121-128, 1993.
DOI : 10.1111/j.1365-2125.1993.tb05677.x

M. Heintzen and B. Strauer, Peripheral Vascular Effects of Beta-Blockers, European Heart Journal, vol.15, issue.suppl C, pp.2-7, 1994.
DOI : 10.1093/eurheartj/15.suppl_C.2

A. Liberati, D. Altman, J. Tetzlaff, C. Mulrow, P. Gotzsche et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, vol.339, issue.jul21 1, p.2700, 2009.
DOI : 10.1136/bmj.b2700

C. Wiysonge, H. Bradley, J. Volmink, B. Mayosi, A. Mbewu et al., Betablockers for hypertension Cochrane Database of Systematic Reviews, 1996.

D. Lima, L. Soares, B. Saconato, H. Atallah, A. Da-silva et al., Beta-blockers for preventing stroke recurrence, Cochrane Database Syst Rev, vol.5, p.7890, 2013.

S. Paravastu, D. Mendonca, D. Silva, and A. , Beta blockers for peripheral arterial disease, Cochrane Database Syst Rev, vol.9, p.5508, 2013.

J. Higgins, D. Altman, P. Gotzsche, P. Juni, D. Moher et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, vol.343, issue.oct18 2, pp.5928-5928, 0182.
DOI : 10.1136/bmj.d5928

M. Puhan, H. Schunemann, M. Murad, T. Li, R. Brignardello-petersen et al., A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis, BMJ, vol.349, issue.sep24 5, pp.5630-5630, 2014.
DOI : 10.1136/bmj.g5630

G. Guyatt, A. Oxman, G. Vist, R. Kunz, J. Brozek et al., GRADE guidelines: 4. Rating the quality of evidence???study limitations (risk of bias), Journal of Clinical Epidemiology, vol.64, issue.4, pp.407-422, 2011.
DOI : 10.1016/j.jclinepi.2010.07.017

G. Guyatt, A. Oxman, R. Kunz, J. Woodcock, J. Brozek et al., GRADE guidelines: 7. Rating the quality of evidence???inconsistency, Journal of Clinical Epidemiology, vol.64, issue.12, pp.1294-302, 2011.
DOI : 10.1016/j.jclinepi.2011.03.017

G. Guyatt, A. Oxman, R. Kunz, J. Woodcock, J. Brozek et al., GRADE guidelines: 8. Rating the quality of evidence???indirectness, Journal of Clinical Epidemiology, vol.64, issue.12, pp.1303-1313, 2011.
DOI : 10.1016/j.jclinepi.2011.04.014

G. Guyatt, A. Oxman, R. Kunz, J. Brozek, P. Alonso-coello et al., GRADE guidelines 6. Rating the quality of evidence???imprecision, Journal of Clinical Epidemiology, vol.64, issue.12, pp.1283-93, 2011.
DOI : 10.1016/j.jclinepi.2011.01.012

G. Guyatt, A. Oxman, V. Montori, G. Vist, R. Kunz et al., GRADE guidelines: 5. Rating the quality of evidence???publication bias, Journal of Clinical Epidemiology, vol.64, issue.12, pp.1277-82, 2011.
DOI : 10.1016/j.jclinepi.2011.01.011

G. Rücker, G. Schwarzer, J. Carpenter, and I. Olkin, Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells, Statistics in Medicine, vol.7, issue.3, pp.721-759, 2009.
DOI : 10.1002/sim.3299

R. Dibianco, S. Singh, P. Shah, G. Newton, R. Miller et al., Comparison of the antianginal efficacy of acebutolol and propranolol. A multicenter, randomized, double-blind placebo-controlled study, Circulation, vol.65, issue.6, pp.1119-1147, 1982.
DOI : 10.1161/01.CIR.65.6.1119

B. Dahlöf, P. Sever, N. Poulter, H. Wedel, D. Beevers et al., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial, The Lancet, vol.366, issue.9489, pp.895-906, 2005.
DOI : 10.1016/S0140-6736(05)67185-1

B. Dahlöf, R. Devereux, S. Kjeldsen, J. S. Beevers, G. De-faire et al., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol, The Lancet, vol.359, issue.9311, pp.995-1003, 2002.
DOI : 10.1016/S0140-6736(02)08089-3

T. Talseth, L. Westlie, and L. Daae, Doxazosin and atenolol as monotherapy in mild and moderate hypertension: A randomized, parallel study with a three-year follow-up, American Heart Journal, vol.121, issue.1, pp.280-285, 1991.
DOI : 10.1016/0002-8703(91)90858-F

N. Committee, Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom, Br Med J Clin Res Ed. 13 févr, vol.296, issue.6620, p.468, 1988.

P. Ott, T. Storm, L. Krusell, H. Jensen, J. Badskjaer et al., Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension, The American Journal of Cardiology, vol.59, issue.14, pp.73-80, 1987.
DOI : 10.1016/0002-9149(87)90161-5

G. Fairhurst, Comparison of bevantolol and atenolol for systemic hypertension, The American Journal of Cardiology, vol.58, issue.12, pp.25-32, 1986.
DOI : 10.1016/0002-9149(86)90594-1

A. Helgeland, R. Strømmen, C. Hagelund, and S. Tretli, Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway, Lancet. 19 avr, vol.1, issue.8486, pp.872-877, 1986.

P. Rubin, D. Clark, D. Sumner, R. Low, L. Butters et al., PLACEBO-CONTROLLED TRIAL OF ATENOLOL IN TREATMENT OF PREGNANCY-ASSOCIATED HYPERTENSION, The Lancet, vol.321, issue.8322, pp.432-436, 1983.
DOI : 10.1016/S0140-6736(83)91436-8

D. Julian, F. Jackson, R. Prescott, P. Szekely, . Controlled et al., The Lancet, pp.1142-1149, 1982.

V. Hansteen, E. Møinichen, E. Lorentsen, A. Andersen, O. Strøm et al., One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial., BMJ, vol.284, issue.6310, p.155, 1982.
DOI : 10.1136/bmj.284.6310.155

H. Persson, E. Rythe-'n-alder, A. Melcher, and L. Erhardt, Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol., Heart, vol.74, issue.2, p.140, 1995.
DOI : 10.1136/hrt.74.2.140

G. Greenberg, P. Brennan, and W. Miall, Effects of diuretic and beta-blocker therapy in the medical research council trial, The American Journal of Medicine, vol.76, issue.2, pp.45-51, 1984.
DOI : 10.1016/0002-9343(84)90956-2

S. Silberstein, D. Dodick, A. Lindblad, K. Holroyd, M. Harrington et al., Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine, Neurology, vol.78, issue.13, pp.976-84, 2012.
DOI : 10.1212/WNL.0b013e31824d5846

J. Pascal and P. Cales, Propranolol in the Prevention of First Upper Gastrointestinal Tract Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal Varices, New England Journal of Medicine, vol.317, issue.14, pp.856-61, 1987.
DOI : 10.1056/NEJM198710013171403

E. Moltzer, M. Raso, F. Karamermer, Y. Boersma, E. Webb et al., Comparison of Candesartan Versus Metoprolol for Treatment of Systemic Hypertension After Repaired Aortic Coarctation, The American Journal of Cardiology, vol.105, issue.2, pp.217-239, 2010.
DOI : 10.1016/j.amjcard.2009.08.674

M. Metra, R. Giubbini, S. Nodari, E. Boldi, M. Modena et al., Differential Effects of ??-Blockers in Patients With Heart Failure : A Prospective, Randomized, Double-Blind Comparison of the Long-Term Effects of Metoprolol Versus Carvedilol, Circulation, vol.102, issue.5, pp.546-51, 2000.
DOI : 10.1161/01.CIR.102.5.546

A. Herrick, P. Waller, K. Berkin, S. Pringle, J. Callender et al., Comparison of enalapril and atenolol in mild to moderate hypertension, The American Journal of Medicine, vol.86, issue.4, pp.421-427, 1989.
DOI : 10.1016/0002-9343(89)90340-9

S. Taylor, B. Silke, A. Ebbutt, G. Sutton, B. Prout et al., A Long-Term Prevention Study with Oxprenolol in Coronary Heart Disease, New England Journal of Medicine, vol.307, issue.21, pp.1293-301, 1982.
DOI : 10.1056/NEJM198211183072101

U. Group, Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39, BMJ, vol.713, issue.20, 1998.

T. Ekbom, B. Dahlöf, L. Hansson, L. Lindholm, B. Scherstén et al., Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives, Journal of Hypertension, vol.10, issue.12, pp.1525-1555, 1992.
DOI : 10.1097/00004872-199210120-00013

O. Garden, P. Mills, G. Birnie, G. Murray, and D. Carter, Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients, Gastroenterology, vol.98, issue.1, pp.185-90, 1990.
DOI : 10.1016/0016-5085(90)91308-S

F. Nielsen, P. Rossing, M. Gall, P. Skøtt, U. Smidt et al., Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy, Diabetes, vol.46, issue.7, pp.1182-1190, 1997.
DOI : 10.2337/diab.46.7.1182

D. Beevers, R. Blackwood, S. Garnham, M. Watson, A. Mehrzad et al., Comparison of lisinopril versus atenolol for mild to moderate essential hypertension, The American Journal of Cardiology, vol.67, issue.1
DOI : 10.1016/0002-9149(91)90100-Y

R. Khattar, R. Senior, P. Soman, R. Van-der-does, and A. Lahiri, Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol, American Heart Journal, vol.142, issue.4, pp.704-717, 2001.
DOI : 10.1067/mhj.2001.116768

J. Mcneil and W. Louis, A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension., British Journal of Clinical Pharmacology, vol.47, issue.S2, pp.163-166, 1979.
DOI : 10.1111/j.1365-2125.1979.tb04774.x

C. Pasotti, A. Capra, G. Fiorella, C. Vibelli, and S. Chierichetti, Effects of pindolol and metoprolol on plasma lipids and lipoproteins., British Journal of Clinical Pharmacology, vol.25, issue.S2, pp.435-439, 1982.
DOI : 10.1111/j.1365-2125.1982.tb01953.x

L. Iliuta, R. Christodorescu, D. Filpescu, H. Moldovan, B. Radulescu et al., Prevention of perioperative atrial fibrillation with betablockers in coronary surgery: betaxolol versus metoprolol, Interactive CardioVascular and Thoracic Surgery, vol.9, issue.1, pp.89-93, 2009.
DOI : 10.1510/icvts.2009.202465

M. Vandenburg, W. Cooper, M. Woollard, W. Currie, and C. Bowker, Reduced peripheral vascular symptoms in elderly patients treated with ?-methyldopa ? A comparison with propranolol, European Journal of Clinical Pharmacology, vol.285, issue.25, pp.325-334, 1984.
DOI : 10.1007/BF00548762

J. Detry, P. Sellier, S. Pennaforte, D. Cokkinos, H. Dargie et al., Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group., British Journal of Clinical Pharmacology, vol.5, issue.Suppl. 22, pp.279-88, 1994.
DOI : 10.1111/j.1365-2125.1994.tb04276.x

J. Salonen and R. Palminteri, Comparison of two doses of betaxolol and placebo in hypertension: A randomized, double-blind cross-over trial, European Journal of Clinical Pharmacology, vol.8, issue.6, pp.491-495, 1982.
DOI : 10.1007/BF00637494

F. Bühler, G. Berglund, O. Anderson, H. Brunner, U. Scherrer et al., Double-Blind Comparison of the Cardioselective ??-Blockers Bisoprolol and Atenolol in Hypertension: The Bisoprolol International Multicenter Study (BIMS), Journal of Cardiovascular Pharmacology, vol.8, issue.11, pp.122-129, 1986.
DOI : 10.1097/00005344-198511001-00022

D. Muinck, E. Buchner-moell, D. Van-de-ven, L. Lie, and K. , Comparison of the Safety and Efficacy of Bisoprolol Versus Atenolol in Stable Exercise-Induced Angina Pectoris: A Multicenter International Randomized Study of Angina Pectoris (MIRSA), Journal of Cardiovascular Pharmacology, vol.19, issue.6, pp.870-875, 1992.
DOI : 10.1097/00005344-199206000-00005

O. Pedersen, Comparison of metoprolol and hydrochlorothiazide as antihypertensive agents, European Journal of Clinical Pharmacology, vol.I, issue.Suppl., pp.381-386, 1976.
DOI : 10.1007/BF00563073

H. Maricq, P. Carpentier, M. Weinrich, J. Keil, Y. Palesch et al., Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison, J Rheumatol. mai, vol.24, issue.5, pp.879-89, 1997.

A. Axford and L. Gilchrist, Propranolol in the treatment of hypertension, Br J Clin Pract. juill, vol.25, issue.7, pp.326-334, 1971.

J. Steiner, R. Cooper, K. Mcpherson, and A. Riley, Effect of beta-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients., British Journal of Clinical Pharmacology, vol.83, issue.6, p.833, 1982.
DOI : 10.1111/j.1365-2125.1982.tb02045.x

H. Wollersheim, J. Lenders, H. Peters, and T. Thien, Influence of cold challenge on finger skin temperature during long-term use of beta-adrenoceptor blocking drugs in hypertensive patients, Int Angiol J Int Union Angiol. sept, vol.6, issue.3, pp.307-318, 1987.

W. Aellig, Clinical pharmacology of pindolol, American Heart Journal, vol.104, issue.2, pp.346-56, 1982.
DOI : 10.1016/0002-8703(82)90125-9

P. Chang, P. Brummelen, . Van, and P. Vermeij, Acute vasodilator action of pindolol in humans, Hypertension, vol.7, issue.1, pp.146-50, 1985.
DOI : 10.1161/01.HYP.7.1.146

O. Thulesius, J. Gjores, and E. Berlin, Vasodilating properties of beta-adrenoceptor blockers with intrinsic sympathomimetic activity., British Journal of Clinical Pharmacology, vol.183, issue.S2, pp.229-230, 1982.
DOI : 10.1111/j.1365-2125.1982.tb01917.x

B. Clark and A. Bertholet, Effects of pindolol on vascular smooth muscle, General Pharmacology: The Vascular System, vol.14, issue.1, pp.117-126, 1983.
DOI : 10.1016/0306-3623(83)90078-2

B. Clark, K. Menninger, and A. Bertholet, Pindolol-the pharmacology of a partial agonist., British Journal of Clinical Pharmacology, vol.7, issue.Suppl.
DOI : 10.1111/j.1365-2125.1982.tb01904.x

R. Freedman, M. Mayes, and S. Sabharwal, Induction of vasospastic attacks despite digital nerve block in Raynaud's disease and phenomenon, Circulation, vol.80, issue.4, pp.859-62, 1989.
DOI : 10.1161/01.CIR.80.4.859

B. Hutton, G. Salanti, A. Chaimani, D. Caldwell, C. Schmid et al., The Quality of Reporting Methods and Results in Network Meta-Analyses: An Overview of Reviews and Suggestions for Improvement, PLoS ONE, vol.17, issue.3, p.92508, 2014.
DOI : 10.1371/journal.pone.0092508.s004